Cagrilintide, Semaglutide

• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 Phase III/IV 14 countries Novo Nordisk A/S
• A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended
  2023-509662-38-00 Phase II 4 countries Novo Nordisk A/S
• A research study to look into the long-term effect on weight loss of CagriSema in people with obesity Ended
  2024-512144-39-00 Phase III 3 countries Novo Nordisk A/S
• REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended
  2023-509600-15-00 Phase III 6 countries Novo Nordisk A/S
• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended
  2023-506924-94-00 Phase III 9 countries Novo Nordisk A/S
• A research study to see how well different doses of CagriSema help people with excess body weight lose weight Ended
  2023-509273-24-00 Phase III 2 countries Novo Nordisk A/S
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended
  2023-508170-28-00 Phase II 10 countries Novo Nordisk A/S
• REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended
  2022-502677-42-00 Phase III 3 countries Novo Nordisk A/S
• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 Phase II 6 countries Novo Nordisk A/S
• REIMAGINE 3: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended
  2022-502679-43-00 Phase III 1 country Novo Nordisk A/S
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended
  2022-502678-18-00 Phase III 15 countries Novo Nordisk A/S
• A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended
  2023-506931-13-00 Phase III 5 countries Novo Nordisk A/S

Showing 1–12 of 12 trials